We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study.
- Authors
Barbanti, Piero; Egeo, Gabriella; Proietti, Stefania; d'Onofrio, Florindo; Aurilia, Cinzia; Finocchi, Cinzia; Di Clemente, Laura; Zucco, Maurizio; Doretti, Alberto; Messina, Stefano; Autunno, Massimo; Ranieri, Angelo; Carnevale, Antonio; Colombo, Bruno; Filippi, Massimo; Tasillo, Miriam; Rinalduzzi, Steno; Querzani, Pietro; Sette, Giuliano; Forino, Lorenzo
- Abstract
This correction notice is for an article titled "Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study" published in the journal Neurology & Therapy. The correction addresses an error in Figure 2d of the article, where the values of HIT-6 at week 12 for high-frequency episodic migraine (HFEM) and chronic migraine (CM) were swapped. The correct values are provided, and the original article has been corrected. The authors of the article are listed at the end of the correction notice.
- Subjects
MIGRAINE; HEADACHE; SAFETY
- Publication
Neurology & Therapy, 2024, Vol 13, Issue 5, p1505
- ISSN
2193-8253
- Publication type
Correction Notice
- DOI
10.1007/s40120-024-00648-z